Wikidata

(Q63399995)

English

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

clinical trial

In more languages

Statements

title
A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis (English)
0 references
medical condition
dermatitis
0 references
eczema
0 references
start time
21 May 2018
0 references
end time
November 2018
0 references
number of participants
29
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63399995&oldid=1857211167"